All In Biotech

Drug Trial Radar · NCT06677060

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

A Phase III, Randomised, Placebo-controlled, Event-driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 11,300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

11,300

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Dec 17, 2029

Study completion Dec 17, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent is required for the optional pre-screening period. The pre-screening assessments do not replace the full screening tests at Visit 1. Upon entering the screening period, all consented participants (after signature of screening ICF) will be screened during an up to 14-day screening period. Participants who meet all screening inclusion/exclusion criteria but are not treated with SGLT2i or are treated for less than 4 weeks will enter a run-in period with dapagliflozin 10 mg once daily for at least 4 weeks (and not more than 6 weeks) before randomisation. Site visits will take place at approximately 2-, 4-, 8-, 16-, and 34-weeks following randomisation. Thereafter visits will occur approximately every 4 months. The study closure procedures will be initiated when the predetermined number of the first secondary endpoint events (ie, the composite of hospitalisation for HF or CV death) is predicted to have occurred i.e., the PACD. In case of premature discontinuation of the blinded study intervention, participants will remain in the study. Unless a participant meets the dapagliflozin specific discontinuation criteria, they will continue to receive open label dapagliflozin 10 mg. It is important that the scheduled study visits and data collection continue according to the study protocol.

Conditions

  • Heart Failure

Interventions

  • Baxdrostat and dapagliflozinDrug

    baxdrostat tablet and dapagliflozin tablet

  • Placebo and dapagliflozinOther

    placebo tablet and dapagliflozin tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV deathTime frame: Event driven; Up to 38 months

Locations

977 sites in 35 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Recruiting

  • Research Site

    Centreville, Alabama · Recruiting

  • Research Site

    Fairhope, Alabama · Recruiting

  • Research Site

    Huntsville, Alabama · Recruiting

  • Research Site

    Mobile, Alabama · Recruiting

  • Research Site

    Sheffield, Alabama · Recruiting

  • Research Site

    Vestavia Hills, Alabama · Recruiting

  • Research Site

    Anchorage, Alaska · Withdrawn

  • Research Site

    Gilbert, Arizona · Recruiting

  • Research Site

    Glendale, Arizona · Completed

  • Research Site

    Tempe, Arizona · Recruiting

  • Research Site

    Tempe, Arizona · Not yet recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Concord, California · Not yet recruiting

  • Research Site

    Daly City, California · Not yet recruiting

  • Research Site

    Dublin, California · Withdrawn

  • Research Site

    Huntington Beach, California · Recruiting

  • Research Site

    Inglewood, California · Recruiting

  • Research Site

    La Jolla, California · Recruiting

  • Research Site

    Lakewood, California · Withdrawn

  • Research Site

    Lincoln, California · Recruiting

  • Research Site

    Loma Linda, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Sacramento, California · Recruiting

  • Research Site

    San Diego, California · Recruiting

  • Research Site

    San Dimas, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    San Francisco, California · Withdrawn

  • Research Site

    Santa Maria, California · Recruiting

  • Research Site

    Sherman Oaks, California · Suspended

  • Research Site

    Thousand Oaks, California · Recruiting

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Englewood, Colorado · Recruiting

  • Research Site

    Bridgeport, Connecticut · Recruiting

  • Research Site

    Stamford, Connecticut · Recruiting

  • Research Site

    Waterbury, Connecticut · Recruiting

  • Research Site

    Boca Raton, Florida · Not yet recruiting

  • Research Site

    Crystal River, Florida · Recruiting

  • Research Site

    Fort Lauderdale, Florida · Withdrawn

Showing 40 of 977 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.